AMARIN CORP PLC\UK
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMRN in the last 30 days.
See all $AMRN insider activity →Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.
Amarin (AMRN) received an updated filing from Sarissa Capital, showing ownership of 25.7M shares, or 6.09% of outstanding shares. The filing includes recent transactions and shared voting power. The data is based on Amarin's Q2 2026 report.
Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AMRN (AMARIN CORP PLC\UK). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AMRN coverage spans earnings, financial news and regulation.
Mixed clinical outcome: failure on primary endpoint may weigh on short-term sentiment, while overall survival improvement could support long-term upside.
The new stake may signal activist interest and could pressure Amarin's board.
Results show improving losses and cash flow, but continued U.S. pricing pressure offsets volume gains, keeping the near-term earnings trajectory mixed.
The filing provides a fresh earnings-style datapoint plus forward-looking expectations tied to its partnered international strategy and U.S. IPE share maintenance.
The print highlights improving cost structure and early traction in the partnered international rollout, while U.S. volumes are expected to stay consistent in FY26.
AlphAI scores every news story that mentions AMRN with an AI model for sentiment and relevance, and aggregates insider trades from AMARIN CORP PLC\UK's SEC EDGAR Form 4 filings. Figures refresh continuously.
Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.
2 min readAmarin (AMRN) received an updated filing from Sarissa Capital, showing ownership of 25.7M shares, or 6.09% of outstanding shares. The filing includes recent transactions and shared voting power. The data is based on Amarin's Q2 2026 report.
1 min readAmarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.
7 min readAMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash
6 min readAmarin (NASDAQ: AMRN) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue fell to $42.2 million from $72.7 million in Q2 2025, while operating expenses dropped 59% to $27.0 million. The company said in-market demand for VASCEPA/VAZKEPA rose 59% YoY across its partner network and U.S. IPE market share increased to 48%. It expects FY 2026 cash growth and continued international volume growth under its Recordati partnership.
7 min readAmarin (AMRN) reported a 42% year-over-year drop in Q2 net revenue, mainly because a prior-year licensing payment was not received. The missing payment was a $25 million upfront from Recordati included in Q2 2025. Operating expenses fell 59% to $27 million. The company cited modest U.S. VASCEPA sales decline from generic competition and expects international growth in 2026.
3 min readAmarin Corporation plc (NASDAQ: AMRN) said it will release its Q2 2026 financial results in a pre-market press release and hold a conference call on July 29, 2026 at 8:00 a.m. ET. The company provided dial-in and webcast details, plus replay access through Jan. 29, 2027.
2 min readAmarin (NASDAQ: AMRN) has welcomed the updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, which endorses icosapent ethyl (IPE) for statin-treated patients with elevated triglycerides to reduce cardiovascular risk. The guideline reinforces that IPE, marketed as VASCEPA/VAZKEPA, reduces cardiovascular events by 25% and supports a broader approach to dyslipidemia management beyond LDL-C lowering. This endorsement is seen as a significant step forward in patient care, addressing residual cardiovascular risk in millions of patients.
4 min readDUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 ( GLOBE NEWSWIRE ) -- Amarin Corporation plc ( NASDAQ: AMRN ) , a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly ...
3 min readDUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 ( GLOBE NEWSWIRE ) -- Amarin Corporation plc ( NASDAQ:AMRN ) , a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly ...
2 min read
